**Background of CPA2 Antibody**
Carboxypeptidase A2 (CPA2) is a zinc-dependent metalloprotease belonging to the carboxypeptidase A/B subfamily, primarily involved in protein metabolism by cleaving hydrophobic C-terminal amino acids. It is synthesized as an inactive zymogen (proCPA2) in the pancreas and activated by trypsin-mediated cleavage. CPA2 plays a critical role in digestive processes, complementing CPA1 in dietary protein breakdown, and may regulate bioactive peptides in specific physiological or pathological contexts.
CPA2 antibodies are essential tools for detecting and studying CPA2 expression, localization, and function. They are widely used in research on pancreatic exocrine disorders, digestive diseases, and cancers where CPA2 dysregulation is observed (e.g., pancreatic adenocarcinoma or neuroendocrine tumors). Specific monoclonal or polyclonal CPA2 antibodies enable applications like Western blotting, immunohistochemistry, and ELISA, aiding in distinguishing CPA2 from homologous enzymes (e.g., CPA1) due to isoform-specific epitopes. Recent studies also explore CPA2's potential roles beyond digestion, including inflammation modulation and tumor microenvironment interactions. Validation of CPA2 antibodies ensures specificity, minimizing cross-reactivity, which is crucial for accurate diagnostic or experimental outcomes in both basic and clinical research.